Anti-VEGF (vascular endothelial growth factor) and anti-EGF (epidermal growth factor) and other monoclonal antibodies developed for use in cancer do possess some degree of specific action on tumor cells yet are not very effective. This evidence concerns the gene EGF and neoplasm.